KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Novartis Ag (NVS) Debt Ratio (2016 - 2025)

Novartis Ag recorded quarterly Debt Ratio of 0.26 in Q4 2025, up 20.3% quarter-over-quarter from 0.22 in Q4 2024, and up 20.3% year-over-year from 0.22 in Q4 2024.

Novartis Ag's Debt Ratio history runs 10 years deep, the most recent figure standing at 0.26 for Q4 2025.

  • In Q4 2025, Debt Ratio rose 20.3% year-over-year to 0.26; the TTM figure through Dec 2025 stood at 0.26 (up 20.3% YoY), while the FY2025 annual figure was 0.26, up 20.3% from the prior year.
  • Debt Ratio came in at 0.26 for Q4 2025 at Novartis Ag, up from 0.22 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.26 in Q4 2025 to a low of 0.01 in Q2 2021.
  • A 5-year average of 0.16 and a median of 0.2 in 2023 frame the typical range for Debt Ratio.
  • Across the five-year window, Debt Ratio slumped 96.45% in 2021 and surged 836.6% in 2022, its largest moves.
  • Novartis Ag's Debt Ratio stood at 0.22 in 2021, then gained by 0.6% to 0.22 in 2022, then fell by 14.43% to 0.19 in 2023, then climbed by 12.87% to 0.22 in 2024, then increased by 20.3% to 0.26 in 2025.
  • According to Business Quant data, Debt Ratio over the past three periods registered 0.26, 0.22, and 0.19 for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 0.37
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 0.27
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 0.47
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 0.38
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 0.62
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 0.39
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 0.31
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 0.51
10 Gsk 88.34 Bn 83.66 Bn - 0.29

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 0.26
Dec 31, 2024 0.22
Dec 31, 2023 0.19
Jun 30, 2023 0.14
Dec 31, 2022 0.22
Jun 30, 2022 0.06
Dec 31, 2021 0.22
Jun 30, 2021 0.01
Dec 31, 2020 0.22
Jun 30, 2020 0.19
Dec 31, 2019 0.18
Dec 31, 2018 0.16
Dec 31, 2017 0.18
Dec 31, 2016 0.00